The investigational antisense oligonucleotide (ASO) therapy BIIB078 may have failed in amyotrophic lateral sclerosis (ALS) clinical trials because it wasn’t adequately reversing key disease processes in the brain and spinal cord. Analyses of body fluids and tissue from participants showed that, while BIIB078 reached key tissues, it couldn’t entirely…
AP-101, AL-S Pharma’s amyotrophic lateral sclerosis (ALS) therapy, was safe and well tolerated and led to clinically meaningful benefits for breathing and survival after one year of treatment. That’s according to topline data from a now-complete Phase 2a study (NCT05039099) that tested the therapy in 73 adults with…
Analyzing single strands of hair has shown researchers that the dynamics of certain metal molecules, such as copper and zinc, in the body are altered in amyotrophic lateral sclerosis (ALS). The scientists hope to build on this discovery to develop a new, noninvasive diagnostic test for the neurodegenerative condition.
Five students from across Canada whose lives have been directly affected by amyotrophic lateral sclerosis (ALS) received scholarships to help them pursue post-secondary education. Each ALS Canada Kevin Daly Bursary recipient will receive $2,500 for the 2025–2026 academic year. The scholarship program is designed for students with a parent,…
Through analyses of blood samples from hundreds of patients, researchers have developed a highly accurate test for diagnosing amyotrophic lateral sclerosis (ALS). The test is based on a unique protein signature in the blood that may be able to detect ALS-related changes up to 10 years before symptoms of…
Coya Therapeutics is preparing to launch a Phase 2 clinical trial in the U.S. to test its COYA 302 as an amyotrophic lateral sclerosis (ALS) treatment. The company said the U.S. Food and Drug Administration accepted its investigational new drug (IND) application after it submitted additional data the agency…
New research is bringing mind-to-speech technology a step closer to reality for people with paralysis, including those with amyotrophic lateral sclerosis (ALS) who lose the ability to speak. A proof-of-principle study shows that a brain-computer interface (BCI) can translate a person’s silent thoughts into spoken words and could provide…
A retrospective analysis using data from two clinical studies and their extension periods showed that Radicava ORS, an oral formulation of edaravone, slows functional decline and helps adults with amyotrophic lateral sclerosis (ALS) live longer. “This analysis provides additional data to help characterize functional outcomes and potential impact of…
A veterinary medication repurposed as a treatment for amyotrophic lateral sclerosis (ALS) helped patients live longer and slowed disease progression in a long-term clinical trial. The drug, NUZ-001 from Neurizon Therapeutics, was generally safe and well tolerated in the open-label extension (NCT06177431) study, which tested the treatment in…
China’s National Medical Products Administration has granted Sineugene Therapeutics permission to begin clinical trials of its gene therapy SNUG01 in people with amyotrophic lateral sclerosis (ALS), clearing the way for clinical trials. The announcement follows a similar decision by the U.S. Food and Drug Administration (FDA). It sets…
